for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Savara Inc

SVRA.OQ

Latest Trade

1.95USD

Change

-0.09(-4.41%)

Volume

232,295

Today's Range

1.92

 - 

2.01

52 Week Range

1.00

 - 

3.58

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.04
Open
2.00
Volume
232,295
3M AVG Volume
87.41
Today's High
2.01
Today's Low
1.92
52 Week High
3.58
52 Week Low
1.00
Shares Out (MIL)
111.63
Market Cap (MIL)
217.68
Forward P/E
-4.96
Dividend (Yield %)
--

Next Event

Savara Inc Annual Shareholders Meeting

Latest Developments

More

Savara Announces Pricing Of Public Offering Of Common Stock

Savara Inc Says Entered Into A Master Services Agreement With Parexel International (IRL) Limited

Savara Announces Proposed Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Savara Inc

Savara Inc., formerly Mast Therapeutics, Inc., is an orphan lung disease company. The Company is engaged in the development and commercialization of novel therapeutics to address unmet medical needs. Its product pipeline include Molgradex, AeroVanc and Aironite. Molgradex is an inhaled formulation of recombinant human GM-CSF. It is developing Molgradex for the treatment of pulmonary alveolar proteinosis (PAP) and nontuberculous mycobacterial (NTM) lung infection. AeroVanc is a vancomycin hydrochloride inhalation powder. It is developing AeroVanc as an antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF). Aironite is a sodium nitrite inhalation solution. Aironite is an investigational product. The Company is developing Molgradex in a pivotal Phase-III clinical trial for the treatment of PAP and in a Phase II a study for NTM lung infection. AeroVanc is in a Phase-III clinical trial.

Industry

Biotechnology & Drugs

Contact Info

900 S Capital of Texas Hwy Ste 150

WEST LAKE HILLS, TX

78746-5436

United States

+1.512.6141848

http://savarapharma.com/

Executive Leadership

Matthew Pauls

Chairman of the Board, Chief Executive Officer

David L. Lowrance

Chief Financial Officer, Secretary

Badrul A. Chowdhury

Chief Medical Officer

Nevan C. Elam

Independent Director

Richard J. Hawkins

Independent Director

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-1.850

2019

-1.950

2020

-0.840

2021(E)

-0.393
Price To Earnings (TTM)
--
Price To Sales (TTM)
847.02
Price To Book (MRQ)
1.64
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
38.99
LT Debt To Equity (MRQ)
38.99
Return on Investment (TTM)
-46.18
Return on Equity (TTM)
-42.41

Latest News

Latest News

BRIEF-Savara Reports Q1 Loss Per Share Of $0.27

* SAVARA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Savara Inc Files Prospectus Relates To Resale Of Up To 47.9 Mln Shares Of Common Stock

* SAVARA INC FILES PROSPECTUS RELATES TO RESALE FROM TIME TO TIME OF UP TO 47.9 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS Source text: (https://bit.ly/3bj0omx) Further company coverage:

BRIEF-Savara Obtains Global Rights To Develop And Commercialize Apulmiq

* SAVARA OBTAINS GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE APULMIQ

BRIEF-Savara Says Enrollment Has Been Terminated In Phase 3 Avail And Phase 2A Encore Studies

* SAVARA INC - ENROLLMENT HAS BEEN TERMINATED IN PHASE 3 AVAIL AND PHASE 2A ENCORE STUDIES

BRIEF-Savara Reports Q4 Loss Per Share Of $0.72

* SAVARA REPORTS FOURTH QUARTER / YEAR-END 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Savara Reports Q1 Loss Per Share $0.88

* SAVARA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up